Results 111 to 120 of about 675 (153)

Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria. [PDF]

Nat Commun
Zhu J, Qin FY, Lei S, Gu R, Qi Q, Lu J, Anderson KE, Wipf P, Ma X.   +8 more
europepmc   +1 more source

Vitiligo: From Pathogenesis to Treatment. [PDF]

J Clin Med
Speeckaert R, Caelenberg EV, Belpaire A, Speeckaert MM, Geel NV.   +4 more
europepmc   +1 more source

04111 Phlebotomy and afamelanotide as an efficient combined treatment of hepatoerythropoietic porphyria

Session 7 – New insights and potential treatment approaches in erythropoietic porphyrias (September 24th, 2024)
Luca Barbieri, Michele De Canio, Caterina Aurizi, Miriam Teoli   +3 more
openaire   +1 more source

Editorial on the Special Issue "Heme Metabolism and Porphyria". [PDF]

Life (Basel)
Di Pierro E, Barman-Aksözen J, Richard E.   +2 more
europepmc   +1 more source

Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria [PDF]

Expert Review of Clinical Pharmacology, 2021
Introduction: In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain after light exposure, which results in a markedly reduced quality of life. Afamelanotide is the first effective approved medical treatment for EPP,
Debby Wensink, Margreet A E M Wagenmakers, Janneke G Langendonk   +2 more
exaly   +3 more sources

Afamelanotide for Erythropoietic Protoporphyria

New England Journal of Medicine, 2015
Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life.We conducted ...
Janneke G Langendonk, Manisha Balwani, Karl E Anderson   +2 more
exaly   +5 more sources